Relay Therapeutics, Inc.

RLAY

Relay Therapeutics, Inc.

RLAY

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-22Shares Purchased (TTM):0Shares Sold (TTM):505,999

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:180,004,085Shares Outstanding:179,849,137Institutional Ownership Pct.:100.09%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	121	205	84	92	114	94	124	152	134	153	144	151
Investments	790	437	471	505	543	617	657	687	554	597	606	659
Accounts Receivable Net Current	-	-	-	-	-	-	-	-	-	-	-	0
Assets Current
Assets Current	928	658	578	624	680	740	809	865	704	770	770	832
Prepaid Expense Current	9	12	18	24	16	22	17	19	10	13	17	17
Other Assets Current	8	5	6	4	8	7	11	7	6	7	3	4
Property Plant And Equipment Net	1	1	2	2	3	5	6	7	8	10	11	11
Operating Lease Right Of Use Asset	37	39	40	41	43	50	52	53	55	56	58	59
Restricted Cash Noncurrent	1	1	1	2	2	2	2	2	3	3	3	3
Finite Lived Intangible Assets Net	-	-	-	-	-	-	-	2	2	2	2	2
Indefinite Lived Intangible Assets Excluding Goodw…	-	-	0	0	0	2	2	-	-	-	2	-
Assets	967	700	621	670	729	799	871	930	773	841	844	907
Liabilities And Stockhold…
Accounts Payable Current	11	4	8	3	5	8	14	7	11	8	9	13
Accrued Liabilities Current	34	21	14	25	23	21	21	33	28	22	15	31
Operating Lease Liability Current	4	4	4	4	4	6	6	6	5	5	5	5
Liabilities Current
Liabilities Current	51	30	26	33	33	37	51	47	45	37	30	51
Deferred Revenue Current	-	-	-	-	-	-	8	-	-	-	-	0
Other Liabilities Current	1	1	0	1	1	2	2	1	1	2	1	1
Operating Lease Liability Noncurrent	27	28	29	30	31	41	43	44	46	47	49	50
Business Combination Contingent Consideration Liab…	-	-	0	-	-	-	0	-	-	11	13	28
Liabilities	77	57	54	62	63	78	94	91	91	96	92	129
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Stockholders Equity	890	642	567	608	666	721	778	839	682	746	752	778
Additional Paid In Capital	3,063	2,730	2,581	2,567	2,551	2,536	2,517	2,498	2,257	2,229	2,153	2,099
Accumulated Other Comprehensive Income Loss Net Of…	-2	-0	1	0	-0	0	-1	3	-1	-1	-0	-3
Retained Earnings Accumulated Deficit	-2,172	-2,088	-2,015	-1,960	-1,886	-1,815	-1,738	-1,662	-1,574	-1,482	-1,401	-1,317
Liabilities And Stockholders Equity	967	700	621	670	729	799	871	930	773	841	844	907
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	450	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	219	189	174	173	172	170	168	167	133	132	127	123
Shares Outstanding	219	189	174	173	172	170	168	167	133	132	127	123

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	8.08%	42.77%	41.85%	-	-	-	-	-	-	-	-	-
2025	-9.64%	-0.60%	12.65%	2.87%	48.14%	96.56%	21.29%	31.09%	13.78%	8.19%	82.97%	33.19%
2024	-3.67%	-1.98%	21.47%	-5.56%	3.76%	-16.27%	-24.80%	-30.24%	-22.40%	-18.40%	-28.27%	-25.07%
2023	-	-	-	-1.25%	-24.71%	-45.75%	9.32%	51.89%	37.57%	-24.79%	-33.49%	-39.26%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	18.27	22.13	22.61	19.14	20.92	19.96	15.95	18.42	15.64	20.73	25.44	16.39
Quick Ratio	18.10	21.73	21.91	18.41	20.43	19.37	15.61	18.02	15.41	20.38	24.89	16.05
Working Capital	877.28M	628.71M	552.70M	591.41M	647.87M	702.61M	758.48M	818.16M	659.23M	732.96M	739.83M	781.05M
Leverage & Debt
Debt to Equity	0.09	0.09	0.10	0.10	0.09	0.11	0.12	0.11	0.13	0.13	0.12	0.17
Debt Ratio	0.08	0.08	0.09	0.09	0.09	0.10	0.11	0.10	0.12	0.11	0.11	0.14
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.02	0.01	0.01	0.01	0.01	0.01	0.04	0.04	0.03	0.02
Days Sales Outstanding TTM	-	-	-	-	-	-	-	-	-	-	-	3.20
Receivables Turnover TTM	-	-	-	-	-	-	-	-	-	-	-	114.16
Per Share Metrics
Free Cash Flow Per Share TTM	-1.16	-1.19	-1.37	-1.02	-1.10	-1.61	-1.76	-2.02	-2.13	-2.20	-2.48	-2.25
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-2,999.67%	-2,776.87%	-1,971.59%	-3,914.38%	-4,105.60%	-4,778.93%	-3,722.07%	-3,794.57%	-1,013.67%	-1,025.24%	-1,460.11%	-1,370.76%
Net Profit Margin TTM	-2,763.91%	-2,554.37%	-1,800.58%	-3,561.43%	-3,728.45%	-4,341.53%	-3,374.72%	-3,449.92%	-916.92%	-931.64%	-1,338.66%	-1,263.49%
Growth Metrics
Net Revenue Growth (1Y)	23.85%	39.03%	53.44%	-16.49%	-76.27%	-78.26%	-60.83%	-61.22%	3,637.58%	2,873.65%	1,749.82%	1,422.12%
Net Income Growth (1Y)	-8.19%	-18.20%	-18.13%	-13.79%	-3.49%	1.30%	-1.25%	5.90%	-6.27%	1.99%	17.72%	12.23%
EPS Growth (1Y)	-22.48%	-23.03%	-31.83%	-29.87%	-25.16%	-21.68%	-15.27%	-7.70%	-14.13%	-5.43%	7.78%	1.83%
Valuation Metrics
P/E TTM	-13.27	-6.56	-5.25	-3.02	-1.90	-1.33	-1.74	-2.88	-2.68	-3.30	-3.95	-3.15
P/B TTM	4.26	2.79	2.56	1.48	0.89	0.61	0.76	1.18	1.27	1.46	1.79	1.32
P/S TTM	366.73	167.62	94.54	107.69	70.92	57.74	58.82	99.22	24.60	30.74	52.83	39.84
Market Cap	3.80B	1.79B	1.45B	899.87M	592.58M	443.39M	588.62M	992.82M	866.00M	1.09B	1.35B	1.03B
Enterprise Value	3.67B	1.58B	1.37B	806.05M	478.63M	347.73M	462.21M	838.35M	729.17M	930.42M	1.21B	873.93M
Calculated Values
Free Cash Flow TTM	-234.31M	-213.39M	-235.87M	-175.66M	-188.85M	-272.62M	-251.13M	-282.56M	-283.24M	-287.50M	-304.44M	-274.53M
Net Debt	-122.53M	-205.93M	-85.35M	-93.82M	-113.94M	-95.66M	-126.41M	-154.48M	-136.83M	-155.57M	-143.74M	-154.04M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-22Sale

Owner: Catinazzo, Thomas

Title: Chief Financial Officer

Shares: 187,163

Price/Share: $16.98

Value: $3,178,027.74

Shares Owned: 177,461

Relationship: Officer

Ownership: Direct

2026-06-22Sale

Owner: Bergstrom, Donald A

Title: President, R&D

Shares: 93,456

Price/Share: $16.94

Value: $1,583,144.64

Shares Owned: 418,557

Relationship: Officer

Ownership: Direct

2026-05-14Sale

Owner: Catinazzo, Thomas

Title: Chief Financial Officer

Shares: 17,717

Price/Share: $12.86

Value: $227,840.62

Shares Owned: 195,178

Relationship: Officer

Ownership: Direct

2026-04-28Sale

Owner: Bergstrom, Donald A

Title: President, R&D

Shares: 1,490

Price/Share: $14.79

Value: $22,037.10

Shares Owned: 418,557

Relationship: Officer

Ownership: Direct

2026-04-28Sale

Owner: Catinazzo, Thomas

Title: Chief Financial Officer

Shares: 972

Price/Share: $14.79

Value: $14,375.88

Shares Owned: 212,895

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-22	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	187,163	16.98	$3,178,027.74	177,461	4
2026-06-22	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	93,456	16.94	$1,583,144.64	418,557	4
2026-05-14	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	17,717	12.86	$227,840.62	195,178	4
2026-04-28	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	1,490	14.79	$22,037.10	418,557	4
2026-04-28	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	972	14.79	$14,375.88	212,895	4
2026-04-28	Rahmer, Peter	Officer	See remarks	Direct	Sale	753	14.79	$11,136.87	275,857	4
2026-04-09	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	1,800	15.00	$27,000.00	213,867	4
2026-03-09	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	17,717	10.06	$178,233.02	231,584	4
2026-01-28	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	1,695	8.45	$14,322.75	249,301	4
2026-01-28	Rahmer, Peter	Officer	See remarks	Direct	Sale	1,354	8.45	$11,441.30	276,610	4
2026-01-28	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	2,686	8.45	$22,696.70	420,047	4
2026-01-06	Patel, Sanjiv	Director,Officer	President and CEO	Direct	Sale	43,168	7.82	$337,573.76	661,041	4
2025-11-03	Patel, Sanjiv	Director,Officer	President and CEO	Direct	Sale	62,073	7.00	$434,511.00	703,215	4
2025-10-29	Rahmer, Peter	Officer	See remarks	Direct	Sale	21,394	7.50	$160,455.00	337,469	4
2025-10-28	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	21,664	7.29	$157,930.56	313,631	4
2025-10-28	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	30,897	7.29	$225,239.13	521,823	4
2025-07-29	Rahmer, Peter	Officer	See remarks	Direct	Sale	15,724	3.68	$57,864.32	377,998	4
2025-07-29	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	18,380	3.68	$67,638.40	335,295	4
2025-07-29	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	18,276	3.68	$67,255.68	371,472	4
2025-07-29	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	26,701	3.68	$98,259.68	552,720	4
2025-07-09	Patel, Sanjiv	Director,Officer	President and CEO	Direct	Sale	61,379	3.57	$219,123.03	765,288	4
2025-04-30	Rahmer, Peter	Officer	See remarks	Direct	Sale	10,739	3.00	$32,217.00	390,081	4
2025-04-30	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	12,943	3.00	$38,829.00	355,376	4
2025-04-30	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	27,472	3.00	$82,416.00	583,490	4
2025-04-28	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	1,644	3.17	$5,211.48	404,328	4
2025-04-23	Patel, Sanjiv	Director,Officer	President and CEO	Direct	Sale	61,422	2.97	$182,423.34	821,667	4
2025-03-27	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	986	2.84	$2,800.24	615,052	4
2025-03-27	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	298	2.84	$846.32	405,972	4
2025-03-27	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	4,864	2.84	$13,813.76	374,567	4
2025-03-27	Rahmer, Peter	Officer	See remarks	Direct	Sale	247	2.84	$701.48	402,184	4
2025-02-13	Patel, Sanjiv	Director,Officer	President and CEO	Direct	Sale	75,324	3.70	$278,698.80	883,089	4
2025-01-30	Rahmer, Peter	Officer	See remarks	Direct	Sale	17,250	4.42	$76,245.00	402,431	4
2025-01-30	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	20,791	4.42	$91,896.22	379,431	4
2025-01-30	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	30,823	4.42	$136,237.66	616,038	4
2025-01-30	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	20,791	4.42	$91,896.22	406,270	4
2025-01-23	Patel, Sanjiv	Director,Officer	President and CEO	Indirect	Sale	125,000	4.78	$597,500.00	199,548	4
2025-01-06	Rahmer, Peter	Officer	See remarks	Direct	Sale	16,576	4.45	$73,763.20	308,754	4
2024-12-27	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	299	4.38	$1,309.62	321,608	4
2024-12-27	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	4,865	4.40	$21,406.00	299,226	4
2024-12-27	Rahmer, Peter	Officer	See remarks	Direct	Sale	400	4.38	$1,752.00	389,663	4
2024-12-27	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	657	4.38	$2,877.66	520,088	4
2024-12-16	Patel, Sanjiv	Director,Officer	President and CEO	Indirect	Sale	100,000	5.00	$500,000.00	574,548	4
2024-10-29	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	2,300	5.95	$13,685.00	304,091	4
2024-10-28	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	1,632	6.06	$9,889.92	321,907	4
2024-10-28	Rahmer, Peter	Officer	See remarks	Direct	Sale	1,621	6.06	$9,823.26	390,063	4
2024-10-28	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	2,688	6.06	$16,289.28	520,745	4
2024-09-27	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	6,457	7.48	$48,298.36	313,193	4
2024-09-27	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	295	7.51	$2,215.45	323,539	4
2024-09-27	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	648	7.51	$4,866.48	523,433	4
2024-09-27	Rahmer, Peter	Officer	See remarks	Direct	Sale	245	7.51	$1,839.95	391,684	4
2024-07-31	Rahmer, Peter	Officer	See remarks	Direct	Sale	13,708	8.19	$112,268.52	391,929	4
2024-07-29	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	2,698	8.85	$23,877.30	524,081	4
2024-07-29	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	1,638	8.85	$14,496.30	323,834	4
2024-07-29	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	10,780	8.68	$93,570.40	319,650	4
2024-07-26	Patel, Sanjiv	Director,Officer	President and CEO	Direct	Sale	36,706	9.07	$332,923.42	766,130	4
2024-06-27	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	648	6.26	$4,056.48	526,779	4
2024-06-27	Rahmer, Peter	Officer	See remarks	Direct	Sale	245	6.26	$1,533.70	432,180	4
2024-06-27	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	295	6.26	$1,846.70	325,472	4
2024-06-27	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	9,373	6.25	$58,581.25	330,430	4
2024-06-05	Rahmer, Peter	Officer	See remarks	Direct	Sale	20,450	7.06	$144,377.00	432,425	4
2024-04-29	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	1,695	6.38	$10,814.10	339,803	4
2024-04-29	Rahmer, Peter	Officer	See remarks	Direct	Sale	1,345	6.38	$8,581.10	513,334	4
2024-04-29	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	1,623	6.38	$10,354.74	325,767	4
2024-04-29	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	2,686	6.38	$17,136.68	527,427	4
2024-03-27	Rahmer, Peter	Officer	See remarks	Direct	Sale	298	7.70	$2,294.60	514,679	4
2024-03-27	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	348	7.70	$2,679.60	341,498	4
2024-03-27	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	348	7.70	$2,679.60	327,390	4
2024-03-27	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	765	7.70	$5,890.50	530,113	4
2024-01-29	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	3,178	9.64	$30,635.92	530,878	4
2024-01-29	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	1,929	9.64	$18,595.56	327,738	4
2024-01-29	Rahmer, Peter	Officer	See remarks	Direct	Sale	1,651	9.64	$15,915.64	514,977	4
2024-01-29	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	2,005	9.64	$19,328.20	341,846	4
2023-12-27	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	977	11.51	$11,245.27	234,056	4
2023-12-27	Rahmer, Peter	Officer	See remarks	Direct	Sale	244	11.51	$2,808.44	316,628	4
2023-12-27	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	294	11.51	$3,383.94	143,851	4
2023-12-27	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	294	11.51	$3,383.94	129,667	4
2023-10-30	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	3,451	6.03	$20,809.53	235,033	4
2023-10-30	Rahmer, Peter	Officer	See remarks	Direct	Sale	1,354	6.03	$8,164.62	316,872	4
2023-10-30	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	1,632	6.03	$9,840.96	129,961	4
2023-10-30	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	1,697	6.03	$10,232.91	144,145	4
2023-09-27	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	294	8.38	$2,463.72	145,842	4
2023-09-27	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	648	8.38	$5,430.24	238,484	4
2023-09-27	Rahmer, Peter	Officer	See remarks	Direct	Sale	244	8.38	$2,044.72	318,226	4
2023-09-27	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	294	8.38	$2,463.72	131,593	4
2023-07-28	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	2,683	11.80	$31,659.40	237,904	4
2023-07-28	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	1,693	11.80	$19,977.40	146,136	4
2023-07-28	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	1,628	11.80	$19,210.40	131,887	4
2023-07-28	Rahmer, Peter	Officer	See remarks	Direct	Sale	1,352	11.80	$15,953.60	316,808	4
2023-06-27	Adams, Brian	Officer	Chief Legal Officer	Direct	Sale	294	12.12	$3,563.28	133,515	4
2023-06-27	Catinazzo, Thomas	Officer	Chief Financial Officer	Direct	Sale	294	12.12	$3,563.28	147,829	4
2023-06-27	Bergstrom, Donald A	Officer	President, R&D	Direct	Sale	647	12.12	$7,841.64	240,587	4
2023-06-27	Rahmer, Peter	Officer	See remarks	Direct	Sale	244	12.12	$2,957.28	318,160	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

100.09%

Inst. Shares: 180,004,085

Shares Outstanding: 179,849,137

2025-12-31

99.28%

Inst. Shares: 170,345,656

Shares Outstanding: 171,586,558

2025-09-30

94.49%

Inst. Shares: 162,884,310

Shares Outstanding: 172,389,209

2025-06-30

96.01%

Inst. Shares: 164,426,985

Shares Outstanding: 171,264,622

2025-03-31

91.98%

Inst. Shares: 155,661,921

Shares Outstanding: 169,233,155

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	180,004,085	179,849,137	100.09%
2025-12-31	170,345,656	171,586,558	99.28%
2025-09-30	162,884,310	172,389,209	94.49%
2025-06-30	164,426,985	171,264,622	96.01%
2025-03-31	155,661,921	169,233,155	91.98%
2024-12-31	158,045,137	142,867,844	110.62%
2024-09-30	150,296,096	140,229,056	107.18%
2024-06-30	120,064,298	132,821,826	90.40%
2024-03-31	119,694,474	130,843,013	91.48%
2023-12-31	115,671,801	122,576,527	94.37%
2023-09-30	116,329,215	122,231,255	95.17%
2023-06-30	113,518,373	121,680,844	93.29%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Relay Therapeutics, Inc. (RLAY) — SEC Financial Statements & Analysis

Relay Therapeutics, Inc. (RLAY) is a biological products, (no diagnostic substances) company, incorporated in DE. Relay Therapeutics, Inc. trades on Nasdaq as: RLAY. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Relay Therapeutics, Inc. reported a 23.85% year-over-year revenue growth, a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 366.73x (TTM), a Price-to-Book (P/B) ratio of 4.26x (TTM), at a market cap of $3.80B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 23.85%
Debt To Equity: 0.09x
P/S TTM: 366.73x
P/B TTM: 4.26x
Market Cap: $3.80B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Relay Therapeutics, Inc. in?

Relay Therapeutics, Inc. (RLAY) operates in the Biological Products, (No Diagnostic Substances) industry.

What is RLAY's market cap?

Relay Therapeutics, Inc. (RLAY) has a market capitalization of $3.80B as of 2026-06-30.

What exchange does RLAY trade on?

Relay Therapeutics, Inc. (RLAY) trades on the Nasdaq.

Where is Relay Therapeutics, Inc. incorporated?

Relay Therapeutics, Inc. is incorporated in DE.